Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-NeuroScience-and-the-Centre-for-Human-Drug-Research-to-Present-DMT-Phase-1-Stroke-Clinical-Data-at-the-Interdis?id=437889
Q&A and Webinar
Here is the link to the recording from last week’s webinar:
Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-CEO-Christopher-J-Moreau-to-Be-Featured-on-Radius-Researchs-Pitch-Deep-Dive-and-QA-Webinar-on-A?id=436475
Outstanding: 21,640,762 for April 4, 2024
Monthly 5th Report
https://webfiles.thecse.com/Algernon_-_CSE_Form_7_-_March_2024.pdf?Is_B3LCsJTGbo_e6ku57Z2tafpM1IKDQ
Is algernon neuro a traded stock by itself.
So no treatment for schemic stroke..
They do minimal things and then wait to see how bad the CNS was damaged..
Than try to rebuild what is lost..
When our drug roves itself..
It will need to be purchased everywhere
Stroke victims have access to treatment.. as the sooner you treat the better..
Our drug will not wait for patients .. caregivers will have to stick it..
Every ambulance, every hospital.. perhaps even every urgent care with me..
Depending on test for type of stroke and Pharma delivery system.. this could be like
Overdose or allergy med.. where they encourage everyone to have..
Depends on stroke test and safety of drug..
Micro dose DMT should be very safe..
That is worldwide in an aging population with increasing cardio system weakness..
$2million in bank.. if they can find clinical partner to share development cost with..
We are very blessed to be here
Neuroplasticity, dendritic spines, 1hr 40mins. He sites many papers, mostly in mouse/rat trials, in this presentation where neuroplasticity is observed, but it seems that the AGN 'microdosing for Stroke' concept is unique.
Yes, the when and where type of data for the clinical trials could be announced soon. Maybe Oregon where it's legal for research?
I've held this long already and will hold through the finish...
...GLTA...
The valuations are going to skyrocket on a positive phase 2a
I had found this presentation a long time ago. Finally found it again and it is a great video including neuroplasticity.
Sure great to see this all finally progressing.
“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,” said Christopher J. Moreau CEO of Algernon. “Algernon is a global leader in this important area of research, and we look forward to further advancing the stroke program through our planned Phase 2a DMT Stroke study.”
Phase 2a Stroke Study Design
Subjects with a confirmed diagnosis of ischemic stroke will be randomized in blinded fashion to receive either DMT or placebo. The primary outcome measure of the study will be safety, and information will be gained on measures of efficacy including preservation of brain tissue, motor recovery, depression and numerous biomarkers linked to the pathophysiology of stroke.
The veteran community has discussed TBI and PTSD issues and treatments involving Psycs. This group may also be a area of recruitment for future stroke/TBI research. There are already a few PTSD studies...
...GLTA...
Algernon going to move forward with 40 patient phase 2 for isechemic stroke.
Is there a Stroke Victim advocacy group which could help cover costs?
Can’t wait for results! 6 days of treatment..
40 patients.. normally a clinical trial takes forever..
How common is an ischemic stroke?
Strokes are very common. Worldwide, strokes rank second among the top causes of death. In the United States, they rank fifth. Strokes are also one of the leading causes of disability worldwide. Ischemic strokes make up about 85% of all strokes.
No shortage of need..
Stroke statistics
In 2021, 1 in 6 deaths from cardiovascular disease was due to stroke.1
Every 40 seconds, someone in the United States has a stroke.2 Every 3 minutes and 14 seconds, someone dies of stroke.1
Every year, more than 795,000 people in the United States have a stroke. About 610,000 of these are first or new strokes.2
About 185,000 strokes—nearly 1 in 4—are in people who have had a previous stroke.2
About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.2
Stroke-related costs in the United States came to nearly $56.5 billion between 2018 and 2019.2 This total includes the cost of health care services, medicines to treat stroke, and missed days of work.
Stroke is a leading cause of serious long-term disability.2 Stroke reduces mobility in more than half of stroke survivors age 65 and older.2
I think the goal will be to administer the first sub psych dose of DMT immediately after diagnosis..
A positive phase 2a.. would be a very large step for algernon
“Investigating neuroplasticity in a clinical setting, as a potential new treatment approach for ischemic stroke patients, is a new and promising area of research,
Most medicines may be cross scripted..
When DMT becomes available for stroke..
I imagine there will be many interested in other illnesses of the CNS for DMT help
Patience and faith in character rewarded!
Great job Chris and algernon
Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Closing-of-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-US-Based-Seyltx-f?id=435013
117 Days counting Today from Nov 22nd
90 days from Nov 22,23
Dec
Jan
Feb
……
Positive trading..
Deal closed maybe ?
Time running out to buy cheap?
Outstanding: 21,640,762 posted March 8, 2024
Monthly 5th Report
https://webfiles.thecse.com/2._Algernon_-_CSE_Form_7_-_February_2024.pdf?xL6dHIb_J8X9xx9tubyGTsjxO5yHy44W
Statement of Executive Compensation – Venture Issuers (for financial year ended August 31, 2023)
Posted Tuesday
https://sedar-filings-backup.thecse.com/00037722/2403061442375471.pdf
Thanks Shell,
This was known. Let hope he doesn’t dilute further. If everything goes right according to their previous news releases they wouldn’t need any cash infusions for a while which is good sign. I am hopeful for issuance of new patents etc.
Outstanding: 21,640,762 posted February 8, 2024
Monthly 5th Report for January filed today
https://webfiles.thecse.com/1._Algernon_-_CSE_Form_7_-_January_2024.pdf?vo61Q.9_pMwV5o_dI3dUQifkB4N2s71C
January 30th, 2024 this happened
Microdose DMT for TBI too. There are Veterans organizations interested and discussions of are widely supported for 'shroom therapy' of PTSD... Proof of therapeutic benefits for stroke, etc.?.
...GLTA...
Agreed
Think this one is not going to have a lot of resistance
You are right about 90 days which should be by Feb 22/24.
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-LOI-for-the-Acquisition-of-its-Chronic-Cough-Research-Program-by-US-Based-Seyltx-for-?id=422342
I read it about it. However, I can’t find the news.
Can you post here the link for the news, please?
Thanks.
They have received two notice of granting two different patents from China within two months which is fast, unusual and excellent.
———
Algernon
Pharmaceuticals
Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat
NASH and NAFLD
Algernon Pharmaceuticals
Nov. 30, 2023 7:00 AM ET • 2 min read
———
Algernon
Pharmaceuticals
Receives Notice of
Intention to Grant from
Chinese Patent Office for Repirinast to Treat
CKD
Algernon Pharmaceuticals
Jan. 31, 2024 7:00 AM ET • 2 min read
Is this increase due to closing of Private offering?
——-
VANCOUVER, British Columbia, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a Canadian clinical stage pharmaceutical development company announces the close of its non-brokered private placement, previously announced on December 12, 2023 and updated on December 27, 2023, for gross proceeds of $280,000 (the “Offering”) of units (the “Units”) at an issue price of $0.075 per Unit.
Certain insiders of the Company participated in the Offering in the amount of $173,505. The participation by insiders in the Offering constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is relying on the exemptions from the valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the Common Shares purchased by insiders, nor the consideration for the Units paid by such insiders, exceeded 25% of the Company's market capitalization. The Company did not file a material change report in respect of the related party transaction at least 21 days before the closing of the Offering, which the Company deems reasonable in the circumstances as the details of the participation by insiders of the Company were not settled until shortly prior to closing the Offering and the Company wished to complete the Offering in an expeditious manner.
I personally think there will be a short squeeze with any major announcement which should be sooner than we expect.
This stock was over $4.00 + a few years ago.
Recent transactions by insiders are good sign. They never owned anything previously. Now, they own 9%.
——-
Recent Insider Transactions
BuyCA$4,50028 Dec 23
Christopher Moreau
BuyCA$4,65027 Dec 23
Christopher Moreau
BuyCA$40,00526 Dec 23
Christopher Moreau
BuyCA$21,00026 Dec 23
James Kinley
Expect closing of $2,000,000 Pharma sale soon as well as data from DMT phase 2?
Also
I think once approved for stroke
DMT micro dose will be highly cross scripted for dementia et al
Thx me too
Although I recommend biying
IMO, patent should be issued in a few months.
Which means what day go for manufacturing the drug in China with a partner ?
It is one of the best market to lunch the drug because of the population need.
Of course, other markets and other options are available as well.
We shall see it.
Note: I am a share holder, please do your own due diligence. I am not recommending to buy, sell or hold.
Thanks 4 your updates.
Outstanding 20,015,762 posted Jan 25th on NEW MD&A
https://webfiles.thecse.com/Algernon_MDA_-_November_30_2023.pdf?kuN9V7XTJdvCciXHAmfcmCkuKqz1pGya
New patent in China
Working right direction
Data from Phase 2 for stroke?
Any ideas on time frame?
Outstanding of 19,509,090 posted 12/28/2023 on MDA
https://webfiles.thecse.com/Algernon_Pharmaceuticals_Inc._August_31_2023_MDA.pdf?L275urqOsYoPM.CeKsuf1a_7SGMQCl3r
Outstanding of 19,509,090 posted 12/28/2023 on MDA
https://webfiles.thecse.com/Algernon_Pharmaceuticals_Inc._August_31_2023_MDA.pdf?L275urqOsYoPM.CeKsuf1a_7SGMQCl3r
Ilfenprodil is readily available in Japan
Think it’s OTC..
Japanese Pharma should see $$ from this patent
Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary Fibrosis
https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Ifenprodil-Patent-in-Japan-for-Idiopathic-Pulmonary-Fibrosis?id=426815
Yes, I saw the same thin in the morning and will read on the weekend.
Very interesting development .
No, there were 14000 shares traded on TSX,
It was spreads issues between bid and offer.
Not so many shares to sell desperatly.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |